Abstract. The 22q11.2 deletion syndrome (22q11DS) encompasses DiGeorge syndrome, velo-cardiofacial syndrome and conotruncal anomaly face syndrome and is due to a microdeletion of chromosome 22q11.2. This is the most frequent known interstitial deletion found in human with an incidence of 1 in 4,000 live births. A large number of clinical findings have been reported in affected patients, including cardiac defects, characteristic facial features, thymic hypoplasia, cleft palate, hypoparathyroidism, learning difficulties and psychiatric disorders. A comprehensive evaluation and follow-up program is necessary for patients with 22q11DS. A striking aspect of the 22q11DS phenotype is its variability, the basis of which remains unclear, and no phenotype-genotype correlation has been made. The structures primarily affected in patients with 22q11DS are derivatives of the embryonic pharyngeal arches and pouches suggesting that haploinsufficiency of the gene(s) on the deleted region, spanning 2-3 Mb, is important in pharyngeal arch/pouch development. Extensive gene searches have been successful in identifying more than 30 genes in the deleted segment. Although standard positional cloning has failed to demonstrate a role for any of these genes in the syndrome, the use of experimental animal models and advanced genome manipulation technologies in mice have been providing an insight into the developmental role of some of these genes, including TBX1. In this review, the clinical features and management of patients with 22q11DS are integrated with our current understanding of the embryological and molecular basis of this syndrome, as presented at
Introduction
The entity of 22q11.2 deletion syndrome A heterozygous deletion within chromosome 22q11.2 (del.22q11) is the genetic basis of the most common interstitial deletion syndrome, the 22q11.2 deletion syndrome (22q11DS) in humans, with an incidence of 1 in 4000-5000 births.1 Most are sporadic in origin, but 10-20% of deletions are inherited as an autosomal dominant trait. In the early 1990's, the deletion was reported in association with three distinct syndromes, namely DiGeorge syndrome (DGS; OMIM]188400), velo-cardio-facial syndrome (VCFS; OMIM]192430) and conotruncal anomaly face syndrome (CAFS; OMIM]217095).2 -4 DGS was originally characterized by congenital heart defects (CHD), hypoparathyroidism and immune deficiency in 1965;5 VCFS was associated with cleft palate, CHD, a distinct facial appearance, and learning difficulties in 1978;6 CAFS was described in 1976 and was characterized by conotruncal CHD, a distinct facial appearance and hyper-nasal voice.7 Clinical genetics have gained from the discovery that these syndromes have overlapping clinical presentations and share a common chromosomal deletion. DGS, VCFS and CAFS are, therefore, part of 22q11DS reflecting various outcomes of the same underlying genetic defect.
The acronym ''CATCH22 (cardiac defects, abnormal facies, thymic hypoplasia, cleft palate, hypocalcemia, and 22q11 deletions)'' was proposed, in 1993, to aid in remembering the main features of the syndrome encompassing DGS, VCFS and CAFS. 8 However, clinical use of this term may be inappropriate because of following reasons:9 1) The term ''Catch-22'' has a negative meaning which represents a situation where it is impossible for you to do anything, originally from Heller's novel entitled ''CATCH 22'';10 2) The term ''A'' referring to ''abnormal facies'' is difficult to accept for patients and their family; 3) Recent studies have revealed that some patients with Opitz G/BBB syndrome (OMIM]145410) or Cayler cardiofacial syndrome (OMIM]125520) have del.22q11, 11, 12 and that the clinical spectrum associated with del.22q11 is much wider than was previously recognized as ''CATCH''. ''22q11DS'' is the appropriate term used now to refer to the wide clinical spectrum due to del.22q11.
Clinical Practice for 22q11.2 Deletion Syndrome

Clinical features
The clinical findings associated with del.22q11 are extensive and highly variable from patient to patient. Main features include CHD, characteristic facial appearance, immunodeficiency from thymic hypoplasia, velopharyngeal dysfunction with or without cleft palate, hypocalcemia due to hypoparathyroidism, developmental and behavioral problems, and psychiatric disorders in adulthood. Over 180 minor manifestations have been reported in association with 22q11DS, such as renal anomalies, short stature, anal atresia, inguinal hernia, hypospadias, squint, facial nerve palsy, scoliosis and thrombocytopenia [http://www.vcfsef.org/ facts.html].
CHD: Approximately 75% of patients with 22q11 DS have CHD. 13 The types of CHD are characterized as conotruncal and aortic arch defects including tetralogy of Fallot (TOF) (@30%), interrupted aortic arch (IAA) type B (@15%), ventricular septal defect (VSD) (@15%), persistent truncus arteriosus (PTA) (@10%) and others (@5%). Del.22q11 is the second most common genetic cause of CHD and is present in @60% of patients with IAA type B, @35% of patients with PTA and @15% of patients with TOF (@55% of patients with TOF plus pulmonary atresia and major aortopulmonary collateral arteries).14,15 CHD significantly affects the prognosis of patients with 22q11DS and is the main cause of mortality. Full evaluations, surgical plans and life-time follow-up for CHD may be required.
Characteristic facial appearance: Almost all patients have some of the following facial features: lateral displacement of inner canthi, narrow palpebral fissures, bloated eyelids, small mouth, hypoplastic mandible, deformed ear lobe, flat nasal bridge and square nose due to hypoplastic ala nasi (Fig. 1) . 15, 16 The facial appearance is most pronounced during childhood, and is sometimes not apparent in neonates or adults. Although it is relatively easy to diagnose patients with typical facial appearance, some patients only have a part of the characteristic facial features making the diagnosis difficult.
Immunodeficiency from thymic hypoplasia: Despite the emphasis on thymus involvement in DGS,5 a severe T cell immunodeficiency, which may require immune reconstruction by thymus or bone marrow transplantation during early infancy, is present only in less than 5% of patients with 22q11DS.13 Maldevelopment of the thymus, however, is common, leading to an absence of mediastinal thymic tissue in over 50% of the patients. Diminished T cell counts in the peripheral blood and slow declines in T cell population with aging are observed in these patients. 17 In patients with 22q11DS, recurrent infections such as bronchopneumonia and otitis media are also common, but have little relationship to specific immunologic laboratory features. These infections may be associated with false aspiration due to velopharyngeal dysfunction and/or structural anomalies of the inner ear (described below). Most patients with 22q11DS can safely be immunized and generate sufficient antibody responses.18
Velopharyngeal dysfunction with or without cleft palate: Velopharyngeal dysfunction can occur for a variety of reasons. In case of structural abnormalities, the term velopharyngeal insufficiency is more appropriate. Cleft palate is present in @10% of patients with 22q11DS. 13 An open cleft is easily recognized, but it requires careful examination to diagnose a submucous cleft. Functional velopharyngeal inadequacy, the more appropriate term for which is velopharyngeal incompetence, is present in more than 30% of patients with 22q11DS with a wide spectrum of severity. 13, 19, 20 Poor mobility of the soft palate can result in the patients' inability to close the velopharyngeal aperture.
The velopharyngeal dysfunction leads to several agedependent problems. 19 In early infancy, it leads to an increased frequency of feeding problem, which often need the placement of a temporary feeding tube, mainly as a result of a poor sucking reflex, a failure of generation of negative pressure suction in oral cavity, and frequent nasal regurgitation. It may also lead to an increased frequency of aspiration pneumonia. In older children, velopharyngeal dysfunction can result in hypernasality, nasal escape creating a poor speech intelligibility and subsequent compensatory speech related behavior.
When evaluating velopharyngeal function, the patient has to repeat standard words and sentences, so cooperation of the patient is essential. Because of developmental delay and behavioral problems, these diagnostic procedures are often difficult to perform in patients under the age of 5 years with 22q11DS. Direct assessment of the velopharyngeal function by viewing the velopharyngeal isthmus and pharynx through combined nasopharyngoscopy and multi-view radiological imaging is possible.21 -23 For patients with mild hypernasality, speech therapy should be started as early as possible to improve velar function by using nasal versus oral airstream exercises and palatal exercises like blowing. The speech therapist must be aware of the learning disabilities and concentration problems in patients with 22q11DS that may negatively influence the outcome of the speech therapy. A pharyngoplasty is recommended in cases of velopharyngeal dysfunction with moderate or severe hypernasal resonance and/or nasal escape.24 This severe dysfunction should be corrected as early as possible, but may be delayed until after surgery for CHD in patients with 22q11DS.
In patients with 22q11DS, recurrent otitis media and conductive hearing loss as a result of chronic serous otitis media are common.13,20 Although velopharyngeal dysfunction and/or structural abnormalities of inner ear may play a role in these conditions, specific and systematic knowledge regarding the ear diseases in 22q11DS is still scarce.
Hypocalcemia due to hypoparathyroidism: Approximately 70% of patients of 22q11DS manifest variable degrees of hypocalcemia reflecting low serum parathyroid hormone (PTH). 13, 25 In the severe cases, hypocalcemia is congenital, with clinical manifestations requiring immediate treatment and continuous administration of active vitamin D and/or calcium.
In patients with 22q11DS, latent hypoparathyroidism is more common than persistent symptomatic hypocalcemia.26,27 While most patients have transient neonatal hypocalcemia with spontaneous resolution in the first years of life, recurrence may be observed later in childhood or adolescence. In patients with latent hypoparathyroidism, the parathyroid secretion is sufficient under basal conditions, but cannot increase in response to hypocalcemic stress, thus leading to hypocalcemia. Such hypocalcemic stress may result from inadequate intakes of calcium, especially when the calcium needs are highest because of rapid skeletal growth, like during infancy, adolescence or pregnancy.27
-29 Normal values of serum calcium and PTH are found in basal condition. But a reduced PTH response to hypocalcemic stress, reflecting partial hypoparathyroidism, may be unmasked by ethylenediaminetetraacetic acid (EDTA) infusions. 30, 31 In cases where the first clinical sign is generalized convulsion due to late onset hypocalcemia, the patient is often misdiagnosed as having epilepsy.
These observations emphasize the need for a regular and continuous survey of the parathyroid status in patients with 22q11DS. Factors or events linked to the other features of the 22q11DS should be considered as they may induce transition from latent to overt hypocalcemia. For example, for surgery of CHD or cleft palate, patients may require calcium supplements while oral intakes are limited. During the treatment of hypocalcemia in patients with 22q11DS, serum calcium should be controlled at low normal levels, above the levels inducing clinical manifestations of hypocalcemia and below those inducing hypercalciuria, which may result in renal stones since the reabsorption of calcium in the kidney is reduced because of low PTH.
Developmental and behavioral problems: Most patients with 22q11DS have cognitive deficits ranging from learning disabilities to mental retardation. 13 The cognitive deficits are not dependent on the presence of associated anomalies.32,33 Mean intelligence quality (IQ) is about 75, but severe mental retardation is rare.33,34 Slow language development and delayed developmental milestones are common in early infancy. Learning disabilities, better verbal abilities than performal abilities, and poor attention and concentration are characteristic. Although most patients can go to regular school, preschool evaluation and early educational intervention for each individual are recommended. The intervention should include training of both verbal (language, articulation, reading, comprehension) and nonverbal areas (motor skills, visualspatial organization, general mathematical training, attention, and social skills), and speech therapy (see the section of velopharyngeal dysfunction) if necessary.
Psychiatric disorders in adulthood:
Recent studies have reported an increased incidence (@20%) of psy-chiatric illness, including schizophrenia and bipolar disorder, in adolescents and adults with 22q11DS.13 Several initial studies indicate that the rate of del.22q11 in schizophrenia is estimated at 2-5% which may be higher in subpopulations with developmental delay. 35, 36 Comprehensive studies of adults with 22q11DS are ongoing to further delineate the phenotype and natural history of associated psychiatric disorders.
Diagnosis and Management
In patients with 22q11DS, the remarkable variability in clinical expression remains a major limiting factor in early diagnosis, and represents a challenge to management and follow-up. To diagnose patients with partial syndrome or atypical manifestations requires careful clinical observation. Conotruncal and aortic arch defects described above are the most early and major signs that help the diagnosis. Minor manifestations almost always are associated, such as minor facial anomalies, signs of velopharyngeal dysfunction, and slender appearance of the fingers. These findings are non-specific, but their absence makes the diagnosis of 22q11DS unlikely. A major anomaly (CHD, cleft palate, symptomatic hypocalcemia) should alert the clinician to look for minor manifestations of the syndrome. Prominent features helpful for diagnosis are variable depending on the patients' age: CHD, severe immunodeficiency (rare) and symptomatic hypocalcemia during early infancy; velopharyngeal dysfunction and developmental delay in preschool age; learning disabilities, latent hypoparathyroidism and psychiatric disorders from school age to adulthood.
A routine test based on fluorescence in situ hybridization (FISH) using probes (TUPLE1 or N25) from the critical deletion region in 22q11.2 is available in most cytogenetic laboratories to confirm diagnosis for patients with both typical and atypical clinical presentations. Rarely, deletions are present in 22q11.2, but not detectable by routine FISH analysis. About 10 cases of such atypical deletions of 22q11.2 have been reported (Fig. 2) .37 -44 Del.22q11 is not detectable by 
Molecular genetics
Despite the heterogeneous clinical presentations, remarkably homogenous deletions in 22q11.2 region are present in patients with 22q11DS, and only a small number of atypical deletions have been reported. Approximately 90% of patients have a typical deleted region (TDR) of @3 Mb, which encompasses an estimated 30 genes, whereas about 8% of patients have a smaller deletion of @1.5 Mb, which encompasses 24 genes ( Fig. 2; Reviewed in 47) . Recent molecular studies characterized low copy repeat sequences in the 22q11 region (LCR22), which flank the TDR and the 1.5 Mb deletion region. Unequal recombination events between flanking LCRs explain the recurrence of deletions of uniform size.48 A similar mechanism of action has been described for other chromosomal deletion syndromes, such as Williams syndrome, and PraderWilli and Angelman syndrome.49 -51 The basis of phenotype variability of 22q11DS remains to be elucidated. There is no genotypephenotype correlation.52 -55 There is phenotype variability even in familial cases, including individuals with monozygotic twins, although affected family members have presumably inherited identical deletions.16,56,57 Suggested explanations for the variable phenotype include allelic variability, variable penetrance and variable expressivity caused by environmental factors or stochastic events during fetal development. As a matter of fact, exposure of early human and mouse embryos to high concentration of vitamin A produces a phenocopy of DGS, and some patients with fetal alcohol syn- 
Developmental biology
The structures primarily affected in patients with 22q11DS are derivatives of the embryonic pharyngeal arches and pouches, suggesting that 22q11DS is a developmental field defect of the pharyngeal apparatus. The pharyngeal arches are bilaterally symmetric structures that develop in a segmental fashion along the anterior-posterior axis, and are composed of a number of different embryonic cell types (Fig. 3) . 59 Each arch has an outer covering of ectoderm, an inner covering of endoderm and a central core of paraxial mesoderm adjacent to an pharyngeal arch artery. Cephalic neural crest cells migrate from the neural fold in the caudal hindbrain to each pharyngeal arch, where they form the mesenchyme that surrounds the pharyngeal arch arteries and the mesodermal core. The mesoderm gives rise to facial and neck muscles, while the neural crestderived mesenchyme contributes to skeletal structures of the face as well as cardiovascular structures. Pharyngeal pouches, formed by the endoderm-derived epithelial layer, give rise to craniofacial organs, including the thymus and parathyroid glands, whereas pharyngeal clefts, formed by the ectoderm-derived epithelial layer, give rise to the epidermis and the sensory neurons of the arch associated ganglia.
Experiments on chick embryos involving ablation of cephalic neural crest cells before their migration from the neural fold result in a phenocopy of the main features of 22q11DS.60,61 Mutations of genes implicated in neural crest development in mouse, such as Pax3 and endothelin-1, can similarly give malformations reminiscent of 22q11DS.62,63 Based on these observations, 22q11DS has been believed to result primarily from abnormal development of neural crest cells that populate the pharyngeal arches, their corresponding pharyngeal arch arteries, and conotruncal region of the heart.
Candidate genes
Approach using experimental animals: Although extensive gene searches have been successful in identifying more than 30 genes in the TDR of 22q11.2 ( Fig. 2) , standard analyses so far have failed to detect mutations in any of these genes in patients with DGS or VCFS phenotype but lacking a cytogenetic aberration (Reviewed in 64). From the aspects of molecular genetics and developmental biology of 22q11DS described above, the gene(s) responsible for phenotype of 22q11DS should be haploinsufficient gene(s) within 22q11.2 region that are expressed and play an important role in developing pharyngeal arches.65 Each pharyngeal arch is composed of an outer epithelium of ectoderm (black), central core of paraxial mesoderm (blue) adjacent to a pharyngeal arch artery, and an inner epithelium of endoderm (green) which forms pharyngeal pouches between each pharyngeal arch. Neural crest cells migrate from the caudal hindbrain and form the mesenchyme (red) that surrounds the pharyngeal arch arteries and the mesodermal core. Arabic numerals represent 1st to 4th pharyngeal arches, and Roman numerals represent 1st to 4th pharyngeal pouches. Note that 1st and 2nd pharyngeal arch defects lead to minor facial anomalies and cleft palate, 3rd and 4th pouch defects lead to hypoplasia of thymus and parathyroid glands, 3rd and 4th arch artery defects lead to aortic arch defects, and defects of the conotruncal region lead to congenital heart defects such as tetralogy of Fallot and persistent truncus arteriosus.
The use of experimental animal models has suggested several attractive candidate genes. HIRA encodes a mammalian ortholog of the yeast Hir1p and Hir2p proteins, which are corepressors of cell cycle-dependent histone gene regulation, and are expressed in neural crest-derived tissues as well as some other tissues in both chick and mouse embryos.66 -68 Embryonic attenuation of Hira by antisense oligonucleotides in chick cardiac neural crest cells results in an increased incidence of PTA.69 Hira interacts biochemically with Pax3 which is a homeodomain protein implicated in neural crest development.70 UFD1L, the ortholog of a highly conserved yeast gene involved in ubiquitin-mediated protein degradation, is also expressed strongly in the pharyngeal arches, head region and limb buds in both chick and mouse embryos.38,71 Ufd1l was identified as a downstream gene of a bHLH transcription factor, dHAND, and was downregulated in dHAND-null mouse embryos that display pharyngeal arch hypoplasia and cardiac outflow tract defects.38 Antisense attenuation of Ufd1l in chick cardiac neural crest cells leads to increased incidence of septation failure of cardiac outflow tract (unpublished observation, 2001). These observations suggest that HIRA and UFD1L may contribute to some aspects of the 22q11DS phenotype. However, mice heterozygous for either Hira or Ufd1l mutation are apparently normal and homozygotes die during early embryogenesis. 72, 73 Crkol (CRKL in human) encodes an SH2-SH3-SH3 adapter protein involved in growth-factor response and focal-adhesion signaling, and is expressed in tissues derived from neural crest cells during development. 74 Mice homozygous null for Crkol are embryonic lethal, and develop a similar phenotype to that of 22q11DS, including conotruncal and aortic arch defects, thymus and craniofacial abnormalities, suggesting a potential contribution of CRKL to the 22q11DS phenotype.74 However, mice heterozygous for Crkol mutation are normal and viable, indicating that Crkol is not haploinsufficient, at least in the mouse.
COMT, which encodes catecol-O-methyltransferase and PRODH, which encodes proline dehydrogenase, are potentially involved in the behavioral and psychiatric phenotype of 22q11DS.75 -77 Comt mutant mice display impairment in emotional behavior. Prodh mutant mice have a deficit in sensorimotor gating that is a neural filtering process, that allows attention to be focused on a given stimulus, and is affected in patients with some psychiatric disorders.
Approach using genomic engineering in the mouse: Recent advanced genome manipulation technologies in mice have more clearly provided an insight into the role of candidate genes for 22q11DS. 47 The human region on chromosome 22q11 and the syntenic, or orthologous, region in the mouse on chromosome 16 (MMU16) are very similar in gene content, although they have a different genomic organization. Several groups have generated deletions in mice in the region on MMU16 to extend the human molecular genetic approaches to identify genes responsible for 22q11DS (Fig. 2) . Lindsay et al. first generated mice with a hemizygous deletion from Es2 to Ufd1l, named Df1/þ, which are carrying one copy of 18 mouse homologues out of the 24 genes that are deleted in patients with the 1.5 Mb deletion.73 Df1/þ mice exhibited aortic arch defects in about 30% of cases at initial analyses. Mice with a homozygous deletion of Df1 region showed early embryonic lethality. Aortic arch anomalies could be corrected in mice that were bred to carry the Df1 deletion on one chromosome 16 and a reciprocal duplication on the other, which restored normal gene dosage. This genetic complementation examination suggested that the aortic arch anomalies observed in Df1/þ mice were due to haploinsufficiency of a gene(s) mapped within the Df1 region. Mice with a hemizygous deletion of @150 kb of the proximal region of the TDR, which encompasses 7 genes, and mice with a hemizygous deletion of a 550 kb region, which encompasses 16 genes partially overlapping Df1 were subsequently generated by Kimber et al. and Puech et al., respectively, but neither of them showed any phenotype of 22q11DS.78,79 Later, mice with hemizygous deletion from Idd to Hira (Lgdel/þ), a region containing the Df1/þ region plus 5 more genes, generated by Merscher et al., exhibited similar types of aortic arch anomalies as Df1/þ in about 50% of cases, as well as parathyroid gland aplasia. 80 Lindsay et al. and Merscher et al. independently narrowed the critical region using chromosomal engineering and rescue transgenesis, and came to the same conclusion that Tbx1 is responsible for the aortic arch phenotype observed in Df1/þ and Lgdel/þ mice. Further establishment and analysis of mice heterozygous for Tbx1 mutation alone by both groups supported this conclusion.72,80 TBX1: TBX1 belongs to the T-box family of transcription factors.81 Members of this family are involved in early development of both vertebrates and invertebrates, including specification of mesoderm and endoderm, and heart and limb morphogenesis (Reviewed in 82). Jerome and Pappaioannou independently reported mice homozygous and heterozygous for a Tbx1 mutation allele.83 According to their report, mice homozygous for Tbx1 mutation died perinatally and displayed virtually all testable features of 22q11DS, including conotruncal defects, abnormal facial features, cleft palate, and hypoplasia of the thymus and parathyroid glands. Mice heterozygous for Tbx1 mutation have only aortic arch patterning defects with a less penetrant phenotype, although they do not reflect the entire phe-notypic spectrum of 22q11DS. These results provided evidence for TBX1 likely being a major genetic determinant in the etiology of 22q11DS. Importantly, mice heterozygous for Tbx1 showed a varying degree of absent or reduced 4th pharyngeal arch arteries, later resulting in aortic arch anomalies, depending on their genetic background. This phenotype nicely matches the abnormalities observed in Df1/þ and Lgdel/þ mice, consistent with the analyses of the two other groups.72,80,83 However, mutational analysis of the coding region of TBX1 in over 200 patients with a clinical suspicion of 22q11DS but without deletion or other detectable rearrangements has so far failed to identify TBX1 gene mutations. 72, 84 To determine the relevance of Tbx1 to the pathogenesis of 22q11DS, we performed detailed expression analyses of mouse and chicken Tbx1 in pharyngeal arch development (Fig. 4) . 85 In mouse embryos at embryonic day (E) 9.5, Tbx1 was preferentially expressed in the pharyngeal arches, the ventral half of the otic vesicle, and in the head. Section in situ hybridization at E10.5 showed expression of Tbx1 in the mesodermal core, adjacent to the pharyngeal arch arteries, and the endodermal epithelium of pharyngeal arches as well as in the head mesenchyme. Whole mount and section in situ hybridization using chicken Tbx1 riboprobe demonstrated a similar expression pattern to that of mouse Tbx1. Interestingly, Tbx1 was not detectable in neural crest-derived mesenchyme in the pharyngeal arches of both mouse and chicken embryos. The expression analysis of Tbx1 in the primary chicken neural crest cells further clearly demonstrated that Tbx1 was not expressed in neural crest cells.
Future directions
A finding that TBX1 haploinsufficiency is likely to be the major determinant of aortic arch defects in patients with 22q11DS is a significant advancement in this field. The pathogenetic basis of 22q11DS would become more clear by future efforts to identify the genes that are targets of TBX1, to define molecular pathways controlling TBX1 expression, and to elucidate the role of TBX1 in cardiovascular and pharyngeal arch development. Although functional mutations have not been identified in patients with a clinical suspicion of , coronal section (B, C) and transverse section (E, F) demonstrate Tbx1 expression (blue or white signals) in the mesodermal core (arrows) and endodermal epithelium (arrow heads) of pharyngeal arches, head mesenchyme (hm) and otic vesicle (ov). B and E are bright field images of C and F, respectively. Asterisks indicate pharyngeal arch arteries. In chick primary neural crest culture cells, HNK-1 (G) and neuropilin-1 (H) are detected by immunocytochemistry and mRNA in situ hybridization, respectively, but Tbx1 is not detectable by mRNA in situ hybridization (I). fg, forgut; da, dorsal aorta; ht, heart. 22q11DS but without the deletion, further extensive mutational analyses are indicated for coding, non coding and regulatory regions of TBX1.
The delineation of the expression pattern of Tbx1 sheds light on the molecular and cellular basis of 22q11DS. Interestingly, Tbx1 is strongly expressed in endoderm and mesoderm cells, but not in neural crest cells during the pharyngeal arch development. 81, 83, 85 This result suggests that the primary lesion of the main features in 22q11DS may not be the neural crest cells, although 22q11DS has been believed to result primarily from abnormal development of neural crest cells as mentioned above. Numerous recent studies have demonstrated that appropriate epithelial-mesenchymal signaling is essential for proper development of the pharyngeal arches, and that the primary impairment of the epithelial endoderm can secondarily affect migration or differentiation of neural crest cells during the pharyngeal arch development.86 -88 Importantly, mutations in genes expressed in either neural crest cells or nonneural crest cells in pharyngeal arches can result in similar aortic arch defects in mice. Future studies are thus required to focus on the signals that mediate interactions between neural crest cells and endoderm cells and/or mesoderm cells in pharyngeal arches to uncover the developmental mechanism of 22q11DS.
Although Tbx1 haploinsufficiency accounts for the aortic arch defects in Df1/þ mice, haploinsufficiency of TBX1 may not be the only cause of the entire clinical presentations of 22q11DS. Df1/þ mice have broader phenotypic features that have not been described in mice heterozygous for Tbx1 mutation, including conotruncal defects (overriding aorta plus ventricular septal defect), hypoplasia of thymus and parathyroid glands, and the behavioral phenotype, still Df1/þ mice do not cover the entire phenotypic spectrum of 22q11DS. 73, 89, 90 The contribution of modifier genes and of additional genes either within (e.g. Ufd1l, Comt and Prodh) or outside (e.g. Hira and Crkol ) of Df1 region on 22q11.2, and elsewhere to various features of 22q11DS, as well as the genetic interaction between these genes and Tbx1, remain to be studied.
TBX1 haploinsufficiency also cannot account for the several reported patients with 22q11DS who have deletions excluding TBX1 locus. The presence of longrange cis-acting genetic elements that regulate the responsible gene(s) on 22q11.2 has been proposed to explain the similar phenotype of patients with atypical deletions.37 In Df1/þ mice, however, a region of only 140 kb, containing Tbx1 and 3 more genes, can fully rescue the aortic arch phenotype when it is introduced using transgenic mice, thus excluding the existence of long-range cis-acting elements regulating Tbx1, at least in the mouse model.72 It is unknown whether such genetic elements may be present in humans, but not conserved in mice.
Finally, the research advances described here should be beneficial to patients with 22q11DS. The continuous efforts to delineate the clinical features with accurate prevalence will lead to effective evaluation and intervention for the patients. Better knowledge for the behavioral and psychiatric phenotype and the phenotype in adult age need to be accumulated over the next few years. One of the ultimate goals for basic research is preventive treatment (and eventual gene therapy) of afflicted infants after discovery of the responsible gene(s) and their function, although it requires much more progress to achieve these interventions. Searching for the upstream or downstream targets of Tbx1 may be the next key step toward the goal. A multifaceted approach to dissect the clinical and genetic aspects of 22q11DS would develop a deeper understanding and a better intervention for patients with 22q11DS or the variety of disorders associated with this syndrome.
